Genesis Molecular AI logo

Genesis Molecular AI

Unifying AI and Biotech to accelerate the discovery of new medicines

162 employees · est. 2019 · Burlingame, United States

VS
Standigm logo

Standigm

The workflow AI drug discovery company

25 employees · est. 2015 · Seoul, Korea South

Standigm is the older company (2019 vs 2015); Genesis Molecular AI is the larger of the two.

Side-by-Side Comparison

Genesis Molecular AI Standigm
Founded
2019 2015 older
Headquarters
Burlingame, United States Seoul, Korea South
Employees
162 larger 25
Industry
AI, Biotechnology, Information Technology AI, Biotechnology, Health Care
Funding Stage
Unknown Series D
Total Funding
$280.13M $371.24M
Funding Rounds
5 8
Services
AI Research and Development, Molecular Design AI Platform, Drug Discovery Solutions, Pharma Partnership Programs AI SaaS & API Solutions, Novel Target Identification, Hit & Lead Optimization, Pipeline Management, Data-Driven AI Platforms
Target Customers
Pharmaceutical Companies, Biotech Researchers, Medical Research Institutions, Drug Development Teams Pharmaceutical Companies, Biotech Startups, Healthcare Research Institutes, Academic and Research Organizations
Taxonomy
Molecular AI, Drug Discovery, Generative AI, Predictive Modelling, Biophysics, Pharmaceuticals, Generative Diffusion Model, Lead Optimization, AI-enabled Drug Design, Biotech Collaborations, Deep Neural Networks, Chemical Synthesis Optimization, Undruggable Targets AI Drug Discovery, Workflow AI, Target Identification, Lead Generation, Drug Repurposing, Molecular Design Workflow, DarkMolFactory, Standigm ASK, Standigm BEST, Standigm Insight, Deep Learning, Automation In Drug Discovery, Novel Target Identification, First-in-Class Lead Compounds
Website
genesistherapeutics.ai standigm.com
Genesis Molecular AI logo

About Genesis Molecular AI

Genesis Molecular AI, founded in 2019 and headquartered in the United States, is advancing the intersection of AI and Biotechnology to expedite new medicine discovery. The company’s proprietary platform, GEMS (Genesis Exploration of Molecular Space), leverages leading-edge generative and predictive...

Standigm logo

About Standigm

Standigm, founded in 2015, is a pioneering workflow AI-driven drug discovery company headquartered in Korea South. The company specializes in utilizing artificial intelligence to streamline and expedite the drug discovery process, targeting industries such as AI, Biotechnology, Health Care, Pharmace...

We will tell you when either one moves

BounceWatch watches Genesis Molecular AI and Standigm for new funding, fast hiring, new executives and a change of software vendor. When one happens, we email you the same day.

Watch both — free

Funding, hiring, leadership and stack changes at Genesis Molecular AI and Standigm — by email.

Frequently Asked Questions

Genesis Molecular AI — Unifying AI and Biotech to accelerate the discovery of new medicines. Standigm — The workflow AI drug discovery company. Both companies operate in related markets but may differ in funding stage, team size, and product focus.
Genesis Molecular AI has raised $280.13M while Standigm has raised $371.24M.
Genesis Molecular AI and Standigm operate in overlapping markets and are frequently compared. Track both companies on Bounce Watch to monitor their growth signals in real time.

Compare Genesis Molecular AI with someone else

Start typing a company name or domain.

Compiled from the BounceWatch company index. We last looked at Genesis Molecular AI on 24 Aug 2026, and Standigm on 15 Jun 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.

One analytics cookie (Google Analytics). Cookie Policy